In March 2025, the Advisory Committee on Dangerous Pathogens (ACDP) advised that clade I mpox no longer meets the criteria for a high consequence infectious disease (HCID) and recommended derogation.

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide class of drug candidates ...

The figure reflects the data as of epidemiological week 25 of 2025, which underscores the disproportionate disease burden on three countries, even as overall cases show a downward trend ...

The investigators at How to Survive explain how Mpox attacks the body and essential steps to survive infection.

The Western Regional Health Directorate has recorded 60 confirmed Mpox cases out of 299 suspected cases from January to ...

In August 2024, the World Health Organization declared a second "Public Health Emergency of International Concern" for mpox.

A new study analyzes blood viral loads during early infection to predict mpox severity, potentially improving treatment ...

Researchers have measured blood virus levels in clade Ia mpox patients during early infection and developed a new approach to help predict the severity of their symptoms.

In August 2024, the World Health Organization declared a second "Public Health Emergency of International Concern" for mpox.

Continuing to vaccinate for mpox through a routine targeted program for gay and bisexual men delivered by sexual health ...